This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
El-Hashemite N , Zhang HB , Henske EP , Kwiatkowski DJ
Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma
Lancet. 2003 Apr;361(9366) :1348-1349
AbstractMutations that inactivate either TSC1 or TSC2 cause tuberous sclerosis. We have used immunoblotting and immunohistochemical analysis to see whether there is phosphorylation of p70 S6 kinase, and the ribosomal S6 protein in anglomyolipomas occurring in tuberous sclerosis. Hamartin (encoded by TSC1) and S6K was expressed in all samples. Tuberin (TSC2) was weak or absent in angiomyolipomas, but present in healthy kidney, whereas, phosphorylated p70 S6 kinase and p56 were present only in angiomyolipomas. Our results indicate activation of a mammalian target of rapamycin metabolic pathway in tuberous sclerosis lesions, which contributes to their growth. We suggest that treatment with rapamycin and its analogues could benefit such patients.
NotesKwiatkowski, DJ,Brigham & Womens Hosp, Dept Med, Div Haematol, 75 Francis St, Boston, MA 02115 USA Article English